NAGE
Niagen Bioscience, Inc.
3.00$
+0.0%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.2% | 57.9% | 52.0% | 50.6% | 49.1% | 44.3% | 40.5% | 38.5% | 40.6% | 39.2% | 38.2% | 35.7% | |
| 34.8% | 42.1% | 48.0% | 49.4% | 50.9% | 55.7% | 59.5% | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% | |
| 3.4% | 5.0% | 11.6% | 18.9% | 17.4% | 9.5% | 5.8% | 5.7% | 6.7% | 5.9% | 6.0% | 4.9% | |
| 51.3% | 40.3% | 42.5% | 83.2% | 86.0% | 74.1% | 51.9% | 53.9% | 39.3% | 29.9% | 18.4% | 20.9% | |
| 68.9% | 53.7% | 61.4% | 126.7% | 156.0% | 123.3% | 93.0% | 101.7% | 85.3% | 67.5% | 54.1% | 53.2% | |
| -34.2% | -11.6% | -13.4% | -77.2% | -105.1% | -67.6% | -33.5% | -40.1% | -25.9% | -6.7% | 7.8% | 11.0% | |
| 1.0% | 3.4% | 1.7% | 0.7% | 0.3% | 1.8% | 0.1% | 0.1% | – | – | – | – | |
| -35.2% | -14.7% | -16.4% | -78.0% | -105.6% | -69.4% | -33.6% | -40.2% | -23.0% | -5.9% | 8.9% | 14.1% | |
| – | 0.0% | – | – | – | – | – | – | – | – | 0.3% | 0.6% | |
| -35.2% | -15.5% | -13.5% | -53.7% | -105.6% | -69.4% | -33.6% | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% | |
| -32.5% | -9.7% | -11.5% | -73.9% | -102.4% | -64.3% | -31.0% | -37.7% | -20.3% | -3.9% | 10.4% | 15.2% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.